Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?

Children on antiretroviral therapy have limited options, particularly if they are failing therapy and live in resource-poor settings. We describe three cases where children accessed third-line antiretroviral therapy off-label, or used them extemporaneously with successful outcomes. We then review th...

Descripción completa

Detalles Bibliográficos
Autores principales: Frigati, Lisa Jane, Rabie, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032725/
https://www.ncbi.nlm.nih.gov/pubmed/35455517
http://dx.doi.org/10.3390/children9040473
_version_ 1784692715748851712
author Frigati, Lisa Jane
Rabie, Helena
author_facet Frigati, Lisa Jane
Rabie, Helena
author_sort Frigati, Lisa Jane
collection PubMed
description Children on antiretroviral therapy have limited options, particularly if they are failing therapy and live in resource-poor settings. We describe three cases where children accessed third-line antiretroviral therapy off-label, or used them extemporaneously with successful outcomes. We then review the evidence for performing this measure. There is an urgent need for appropriate formulations to treat young children who require a third-line or salvage regimen.
format Online
Article
Text
id pubmed-9032725
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90327252022-04-23 Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available? Frigati, Lisa Jane Rabie, Helena Children (Basel) Case Report Children on antiretroviral therapy have limited options, particularly if they are failing therapy and live in resource-poor settings. We describe three cases where children accessed third-line antiretroviral therapy off-label, or used them extemporaneously with successful outcomes. We then review the evidence for performing this measure. There is an urgent need for appropriate formulations to treat young children who require a third-line or salvage regimen. MDPI 2022-03-30 /pmc/articles/PMC9032725/ /pubmed/35455517 http://dx.doi.org/10.3390/children9040473 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Frigati, Lisa Jane
Rabie, Helena
Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?
title Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?
title_full Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?
title_fullStr Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?
title_full_unstemmed Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?
title_short Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?
title_sort third-line antiretroviral therapy: what do we do when the appropriate formulations are not available?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032725/
https://www.ncbi.nlm.nih.gov/pubmed/35455517
http://dx.doi.org/10.3390/children9040473
work_keys_str_mv AT frigatilisajane thirdlineantiretroviraltherapywhatdowedowhentheappropriateformulationsarenotavailable
AT rabiehelena thirdlineantiretroviraltherapywhatdowedowhentheappropriateformulationsarenotavailable

Ejemplares similares